ExoLuminate Study for Early Detection of Pancreatic Cancer

ExoLuminate is a nationally-enrolling registry study designed for earlier detection of cancer in those patients that are at an elevated risk or clinically-suspicious for pancreatic ductal adenocarcinoma (PDAC).Those with elevated risk for PDAC can include individuals with intraductal papillary mucinous neoplasms, a family history of pancreatic cancer, germline mutations in genes known to be associated with cancer, a personal or family history of pancreatitis, or new onset diabetes after age 50.The goal of the study is to compare the performance of ExoVerita™ assay in early detection of PDAC to current standard-of-care methods of surveillance.

Inclusion Criteria:≥18 years oldCohort 1 or Cohort 2Capable of giving informed consentAble to provide a blood sampleTested for the presence of deleterious germline mutations associated with PDAC or willing to provide samples for germline genetic analysis.Exclusion Criteria:< 18 years oldPregnancyUndergoing any active treatment from of an active cancer diagnosis (except for skin malignancies).History of fainting or other adverse effects when blood is drawn.Unwilling to provide germline mutation information or samples for germline genetic analysisAny condition that, in the opinion of the investigator, should preclude enrollment.